Free tool
Drug Trial Radar: Cardiovascular and metabolic
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
73
Active, not recruiting, industry sponsors, Cardiovascular and metabolic, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting187
- Completed2,126
73 trials
Showing 1 to 25, recently updated first.
- Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic CancerActive, not recruiting
Aulos Bioscience, Inc.Industry
NCT05267626 · 159 participants (planned) · Start Apr 4, 2022 · Primary completion Feb 28, 2027
Drug: AU-007; Aldesleukin and 2 more · For: Advanced Solid Tumor; Metastatic Cancer; Cutaneous Melanoma and 1 more
Sites: Miami, Florida; Grand Rapids, Michigan; Minneapolis, Minnesota · 17 sites in all
- A Study of Eloralintide (LY3841136) in Participants With Obesity or OverweightActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07738614 · 56 participants (planned) · Start Jul 31, 2026 · Primary completion Dec 2026
Drug: Eloralintide; Placebo and 1 more · For: Obesity; Overweight
Sites: San Antonio, Texas; Singapore, Singapore
- A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With ObesityActive, not recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06745284 · 64 participants · Start Mar 26, 2025 · Primary completion Nov 1, 2026
Drug: Survodutide; Semaglutide · For: Obesity
Sites: Orlando, Florida; Baton Rouge, Louisiana
- A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DMPivotal-lookingActive, not recruiting
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT06845202 · 105 participants · Start Mar 3, 2025 · Primary completion Aug 31, 2027
Drug: ALN-4324; Placebo · For: Obese or Overweight Healthy Volunteers; Type 2 Diabetes Mellitus (T2DM)
Sites: Montclair, California; Washington D.C., District of Columbia; Miami, Florida · 22 sites in all
- Evaluate LAE102 in Healthy and Overweight/Obese SubjectsPivotal-lookingActive, not recruiting
Laekna LimitedIndustry
NCT06493084 · 160 participants (planned) · Start Jun 25, 2024 · Primary completion Jun 30, 2027
Drug: LAE102 intravenous administration; placebo intravenous administration and 4 more · For: Overweight and Obese Volunteers
Sites: Shanghai, China
- A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy ParticipantsActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT07534592 · 48 participants · Start Apr 16, 2026 · Primary completion Jan 25, 2027
Drug: Elecoglipron; Atorvastatin and 1 more · For: Healthy Participants
Sites: Glendale, California; Brooklyn, Maryland
- A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.Active, not recruiting
AbbVieAbbVie (ABBV)
NCT07514260 · 24 participants · Start Mar 31, 2026 · Primary completion Dec 2026
Drug: ABBV-295; Placebo for ABBV-295 · For: Healthy Volunteer
Sites: Anaheim, California
- A Study to Learn About the Study Medicine Called PF-08653944 in Otherwise Healthy Chinese Adults With Overweight or ObesityActive, not recruiting
PfizerPfizer (PFE)
NCT07845513 · 11 participants · Start Oct 13, 2026 · Primary completion Feb 21, 2027
Drug: PF-08653944 · For: Overweight; Obesity; Healthy Adults
Sites: Beijing, China
- A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With ObesityActive, not recruiting
AbbVieAbbVie (ABBV)
NCT07291232 · 80 participants · Start Nov 19, 2025 · Primary completion Apr 2027
Drug: ABBV-295; Placebo · For: Obesity
Sites: Anaheim, California; Grayslake, Illinois
- A Study to Learn How the Study Medicine Called PF-08653945 is Taken up Into the Blood in Adults With Overweight or ObesityActive, not recruiting
PfizerPfizer (PFE)
NCT07725809 · 57 participants (planned) · Start Jul 23, 2026 · Primary completion Jan 13, 2027
Drug: PF-08653945 · For: Overweight; Obesity; Healthy
Sites: Brussels, Belgium
- A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or OverweightActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07499050 · 30 participants (planned) · Start Mar 30, 2026 · Primary completion Jan 9, 2027
Drug: RO7795081; Placebo · For: Healthy Volunteers; Overweight or Obesity
Sites: Nanjing, China; Shanghai, China
- A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)Pivotal-lookingActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06836609 · 118 participants · Start Apr 28, 2025 · Primary completion Aug 17, 2027
Drug: ALN-CIDEB; Placebo · For: Metabolic Dysfunction-Associated Steatotic Liver Disease; Metabolic Dysfunction-Associated Steatohepatitis
Sites: Chandler, Arizona; Tucson, Arizona; London, United Kingdom · 4 sites in all
- A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes MellitusPivotal-lookingActive, not recruiting
Arrowhead PharmaceuticalsIndustry
NCT06700538 · 190 participants · Start Dec 4, 2024 · Primary completion Oct 15, 2027
Drug: ARO-INHBE; Placebo and 1 more · For: Obesity
Sites: Camberwell, Australia; Charlestown, Australia; Maroochydore, Australia · 15 sites in all
- A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or ObesityActive, not recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07768813 · 44 participants · Start Sep 2, 2026 · Primary completion Dec 8, 2026
Drug: Survodutide formulation B2 · For: Healthy; Obesity
Sites: Mannheim, Germany
- Safety, Tolerability, PK and PD of ADX-850 in Participants With HypertensionActive, not recruiting
ADARx Pharmaceuticals, Inc.Industry
NCT06205628 · 28 participants · Start Mar 21, 2024 · Primary completion Oct 6, 2026
Drug: ADX-850; Placebo · For: Hypertension; Hypertension,Essential
Sites: Adelaide, Australia; Nedlands, Australia; Perth, Australia
- A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and OverweightPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT06151964 · 166 participants · Start Sep 29, 2023 · Primary completion Jan 29, 2027
Drug: AZD9550; placebo and 1 more · For: Overweight and Obesity
Sites: Graz, Austria; Vienna, Austria; Surrey, Canada · 15 sites in all
- A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)Active, not recruiting
Vasa TherapeuticsIndustry
NCT07219511 · 42 participants (planned) · Start Nov 4, 2025 · Primary completion Nov 2026
Drug: VS-041 · For: Heart; Heart Failure With Preserved Ejection Fraction (HFPEF)
Sites: Little Rock, Arkansas; Huntington Beach, California; Santa Maria, California · 21 sites in all
- A Study of Zovaglutide (ZT002 Injection) in Participants With Impaired Kidney Function and Healthy ParticipantsActive, not recruiting
Beijing QL Biopharmaceutical Co.,LtdIndustry
NCT07443059 · 40 participants (planned) · Start Apr 13, 2026 · Primary completion Dec 3, 2026
Drug: Zovaglutide; Zovaglutide and 2 more · For: Overweight , Obesity
Sites: Xiamen, China; Jinan, China; Chengdu, China
- A Study to Investigate the Effects of Zovaglutide (ZT002 Injection) on QTc Interval in Healthy AdultsActive, not recruiting
Beijing QL Biopharmaceutical Co.,LtdIndustry
NCT07697846 · 40 participants (planned) · Start Jul 15, 2026 · Primary completion Jan 13, 2027
Drug: ZT002 injection; ZT002 injection matching placebo · For: Overweight, Obesity
Sites: Beijing, China
- A Study of SHR-2906 Injection in Healthy Subjects With a Single Dose and in Obese Patients With Multiple DosesActive, not recruiting
Beijing Suncadia Pharmaceuticals Co., LtdIndustry
NCT07280936 · 76 participants · Start Jan 5, 2026 · Primary completion Dec 2026
Drug: SHR-2906 Injection; SHR-2906 Injection Placebo · For: Obesity; Overweight
Sites: Hangzhou, China
- Drug-drug Interaction Study of ZT002 Injection in Overweight and Obese ParticipantsActive, not recruiting
Beijing QL Biopharmaceutical Co.,LtdIndustry
NCT07550816 · 60 participants (planned) · Start May 27, 2026 · Primary completion Dec 5, 2026
Drug: ZT002 injection, metformin, warfarin; ZT002 injection, rosuvastatin, digoxin · For: Overweight,Obesity
Sites: Chengdu, China
- Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2DPivotal-lookingActive, not recruiting
Alveus Therapeutics, Inc.Industry
NCT07399678 · 180 participants (planned) · Start Dec 29, 2025 · Primary completion Oct 2027
Drug: ALV-100; Placebo · For: Overweight or Obese Adults; Overweight or Obese, Type 2 Diabetes
Sites: Miami, Florida; Columbus, Ohio; San Antonio, Texas
AstraZenecaAstraZeneca (AZN)
NCT07013643 · 100 participants · Start Jun 4, 2025 · Primary completion Jul 9, 2027
Drug: AZD6234; Ethinyl estradiol/Levonorgestrel (EE/LEVO) and 2 more · For: Healthy Participants
Sites: Glendale, California; Brooklyn, Maryland
- A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway ImpairmentPivotal-lookingActive, not recruiting
Rhythm Pharmaceuticals, Inc.Industry
NCT06239116 · 111 participants · Start Mar 5, 2024 · Primary completion May 7, 2027
Drug: Part A: RM-718 or placebo (matched to specific RM-718 dose cohort); Part B: RM-718 or placebo (matched to specific RM-718 dose cohort) and 2 more · For: Hypothalamic Obesity; Prader-Willi Syndrome; PWS
Sites: Birmingham, Alabama; Chicago, Illinois; Boston, Massachusetts · 7 sites in all
- A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 DiabetesActive, not recruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT05791201 · 7 participants · Start May 16, 2023 · Primary completion Mar 12, 2027
Drug: VX-264 · For: Type 1 Diabetes
Sites: Miami, Florida; Chicago, Illinois; Boston, Massachusetts · 16 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.